How to manage Pseudomonas aeruginosa infections

Infections with have become a real concern in hospital-acquired infections, especially in critically ill and immunocompromised patients. The major problem leading to high mortality lies in the appearance of drug-resistant strains. Therefore, a vast number of approaches to develop novel anti-infectiv...

Full description

Saved in:
Bibliographic Details
Published in:Drugs in Context Vol. 7; pp. 212527 - 18
Main Authors: Bassetti, Matteo, Vena, Antonio, Croxatto, Antony, Righi, Elda, Guery, Benoit
Format: Journal Article
Language:English
Published: England BioExcel Publishing Ltd 2018
Subjects:
bloodstream infection
ceftazidime-avibactam
ceftolozane-tazobactam
multidrug resistance
new antibiotics
Pseudomonas aeruginosa
Review
ventilator associated pneumonia
multidrug resistance
new antibiotics
ventilator associated pneumonia
ceftolozane-tazobactam
Pseudomonas aeruginosa
bloodstream infection
ceftazidime-avibactam
ISSN:1745-1981, 1740-4398, 1740-4398
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Infections with have become a real concern in hospital-acquired infections, especially in critically ill and immunocompromised patients. The major problem leading to high mortality lies in the appearance of drug-resistant strains. Therefore, a vast number of approaches to develop novel anti-infectives is currently pursued. Diverse strategies range from killing (new antibiotics) to disarming (antivirulence) the pathogen. In this review, selected aspects of antimicrobial resistance and infection management will be addressed. Many studies have been performed to evaluate the risk factors for resistance and the potential consequences on mortality and attributable mortality. The review also looks at the mechanisms associated with resistance - is a pathogen presenting a large genome, and it can develop a large number of factors associated with antibiotic resistance involving almost all classes of antibiotics. Clinical approaches to patients with bacteremia, ventilator-associated pneumonia, urinary tract infections and skin soft tissue infections are discussed. Antibiotic combinations are reviewed as well as an analysis of pharmacokinetic and pharmacodynamic parameters to optimize treatment. Limitations of current therapies, the potential for alternative drugs and new therapeutic options are also discussed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1745-1981
1740-4398
1740-4398
DOI:10.7573/dic.212527